Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10842872 | BAUSCH LOMB IRELAND | Fluorescein and benoxinate compositions |
Nov, 2037
(14 years from now) | |
US10632197 | BAUSCH LOMB IRELAND | Fluorescein and benoxinate compositions |
Nov, 2037
(14 years from now) | |
US10293047 | BAUSCH LOMB IRELAND | Fluorescein and benoxinate compositions |
Nov, 2037
(14 years from now) |
Drugs and Companies using BENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM ingredient
Market Authorisation Date: 09 March, 2020
Treatment: Procedures in adult and pediatric patients requiring a disclosing agent in combination with a topical ophthalmic anesthetic.; Ocular examination, intraocular pressure measurement, or removal of foreign bodies or sutures, in adult and pediatric patients requiring a disclosing agent in combination with a topical ophthalmic anesthetic
Dosage: SOLUTION/DROPS;OPHTHALMIC
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic